AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21356018 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush T3 - bristles on different planes, straight and circular arrangement
Number of subjects: 27
Study 21356018 — intervention group
Group type: EXPERIMENTAL
Intervention: All toothbrush models
Number of subjects: 27
Study 18281352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative weekly breastfeeding duration by 13 weeks
Number of subjects: 255
Study 18281352 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 255
Study 16781249 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 12
Study 16781249 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (control)
Number of subjects: 12
Study 15271868 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose triptorelin (1.87 mg)
Number of subjects: 180
Study 15271868 — intervention group
Group type: COMPARATOR
Intervention: Full-dose triptorelin (3.75 mg)
Number of subjects: 180
Study 10858349 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (2.5 mg/kg twice a day)
Number of subjects: 557
Study 10858349 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B capsules (500 mg orally four times a day)
Number of subjects: 557
Study 9089968 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 70
Study 9089968 — intervention group
Group type: COMPARATOR
Intervention: Standard lobectomy (control group)
Number of subjects: 70
Study 9089968 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard lobectomy)
Number of subjects: 70
Study 8456902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 gm of n‐3 fatty acid per day)
Number of subjects: 47
Study 8456902 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil or no oil supplementation)
Number of subjects: 47
Study 3510762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole plus aspirin
Number of subjects: 407
Study 3510762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 31012225 — intervention group
Group type: EXPERIMENTAL
Intervention: iVAPS AutoEPAP
Number of subjects: 38
Study 31012225 — intervention group
Group type: COMPARATOR
Intervention: iVAPS manual EPAP
Number of subjects: 38
Study 30222861 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Muscle Tension (AMT) at strategic time points (n = 250)
Number of subjects: 734
Study 30222861 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Muscle Tension (AMT) during entire donation (n = 244)
Number of subjects: 734
Study 30222861 — intervention group
Group type: COMPARATOR
Intervention: Standard blood donation control (n = 240)
Number of subjects: 734
Study 26891646 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercise (SSE)
Number of subjects: 36
Study 26891646 — intervention group
Group type: COMPARATOR
Intervention: Control (relaxed by lying supine quietly)
Number of subjects: 36
Study 24792708 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation in a multisensory stimulation environment (MSSE)
Number of subjects: 0
Study 24792708 — intervention group
Group type: COMPARATOR
Intervention: One-to-one activity sessions
Number of subjects: 0
Study 23129085 — intervention group
Group type: EXPERIMENTAL
Intervention: Short behavioral counseling intervention on strategies to decrease screen time
Number of subjects: 0
Study 23129085 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 20142307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation alone
Number of subjects: 19
Study 20142307 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine alone
Number of subjects: 19
Study 20142307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sleep deprivation and morphine
Number of subjects: 19
Study 20142307 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine on dosing day with sleep deprivation
Number of subjects: 19
Study 20142307 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day buprenorphine dosing
Number of subjects: 19
Study 20142307 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 19
Study 18664888 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatments for PTSD
Number of subjects: 239668
Study 18664888 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatments for PTSD targeting combat-related trauma
Number of subjects: 239668
Study 16599101 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate tablet (20 mg)
Number of subjects: 1600
Study 16599101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1600
Study 16599101 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1600
Study 12166540 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg, two inhalations twice daily (n=390)
Number of subjects: 586
Study 12166540 — intervention group
Group type: COMPARATOR
Intervention: Budesonide plus formoterol administered via separate inhalers (n=190)
Number of subjects: 586
Study 10604851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 0
Study 10604851 — intervention group
Group type: COMPARATOR
Intervention: Air inhalation (control)
Number of subjects: 0
Study 7546830 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 0
Study 7546830 — intervention group
Group type: COMPARATOR
Intervention: Other bisphosphonates
Number of subjects: 0
Study 1714669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonnecor (2 x 0.1 to 1 x 0.3 mg/kg body weight)
Number of subjects: 68
Study 1714669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonnecor
Number of subjects: 68
Study 1714669 — intervention group
Group type: COMPARATOR
Intervention: Verapamil retard
Number of subjects: 68
Study 377449 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 0
Study 377449 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ACSA)
Number of subjects: 0
Study 30128855 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 50
Study 30128855 — intervention group
Group type: COMPARATOR
Intervention: Gentle exercise
Number of subjects: 50
Study 30128855 — intervention group
Group type: COMPARATOR
Intervention: Survivorship support
Number of subjects: 50
Study 27918733 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information given verbally with details of operative procedures and recovery, and by watching a movie on single implant surgery (movie group)
Number of subjects: 60
Study 27918733 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information given verbally, with details of operation and recovery (group 1)
Number of subjects: 60
Study 27918733 — intervention group
Group type: COMPARATOR
Intervention: Basic information given verbally but devoid of details of the operative procedures and recovery (control group)
Number of subjects: 60
Study 25399033 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI intervention
Number of subjects: 848
Study 25399033 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 848
Study 23958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplement (200 g/d)
Number of subjects: 48
Study 23958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalgae (MA) supplement (200 g/d)
Number of subjects: 48
Study 23958023 — intervention group
Group type: COMPARATOR
Intervention: Control (no marine oil supplement)
Number of subjects: 48
Study 23958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasture management system (PAS)
Number of subjects: 48
Study 23958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Confinement management system (CONF)
Number of subjects: 48
Study 21350032 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated version of GMFM-66 (item set approach)
Number of subjects: 26
Study 21350032 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated version of GMFM-66 (basal and ceiling approach)
Number of subjects: 26
Study 21350032 — intervention group
Group type: COMPARATOR
Intervention: Full GMFM-66
Number of subjects: 26
Study 19116800 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia treatment study volunteers (n = 120)
Number of subjects: 226
Study 19116800 — intervention group
Group type: COMPARATOR
Intervention: Clinical patients seeking treatment (n = 106)
Number of subjects: 226
Study 17263835 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once-daily (n = 122)
Number of subjects: 242
Study 17263835 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice-daily plus phenethicillin 250 mg four-times-daily (n = 120)
Number of subjects: 242
Study 17263835 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 242
Study 17263835 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin plus phenethicillin
Number of subjects: 242
Study 15269617 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced RTUF
Number of subjects: 260
Study 15269617 — intervention group
Group type: COMPARATOR
Intervention: Imported RTUF
Number of subjects: 260
Study 15269617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 260
Study 11736723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 19
Study 11736723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9418709 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens
Number of subjects: 100
Study 9418709 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogen + methyltestosterone
Number of subjects: 100
Study 9418709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8500785 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg metoclopramide
Number of subjects: 24
Study 8500785 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg metoclopramide
Number of subjects: 24
Study 8500785 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg metoclopramide
Number of subjects: 24
Study 8500785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3425810 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative nasogastric decompression
Number of subjects: 56
Study 3425810 — intervention group
Group type: COMPARATOR
Intervention: No postoperative nasogastric decompression
Number of subjects: 56
Study 2553879 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line MVP (mitomycin, vinblastine, and cisplatin)
Number of subjects: 699
Study 2553879 — intervention group
Group type: EXPERIMENTAL
Intervention: VP (vinblastine and cisplatin)
Number of subjects: 699
Study 2553879 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP/CAMP (mitomycin, vinblastine, cisplatin alternating with cyclophosphamide, doxorubicin, methotrexate, and procarbazine)
Number of subjects: 699
Study 2553879 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 699
Study 2553879 — intervention group
Group type: EXPERIMENTAL
Intervention: Iproplatin
Number of subjects: 699
Study 2553879 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line MVP
Number of subjects: 699
Study 2553879 — intervention group
Group type: COMPARATOR
Intervention: Combination regimens
Number of subjects: 699
Study 2553879 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with MVP
Number of subjects: 699
Study 31550354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) trivalent inactivated vaccine
Number of subjects: 60
Study 31550354 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) trivalent inactivated vaccine
Number of subjects: 60
Study 31080008 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Needle Celiac Neurolysis
Number of subjects: 34
Study 31080008 — intervention group
Group type: COMPARATOR
Intervention: Double Needles Celiac Neurolysis
Number of subjects: 34
Study 31080008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 27429029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (n = 152)
Number of subjects: 300
Study 27429029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 148)
Number of subjects: 300
Study 27429029 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (n = 300)
Number of subjects: 300
Study 27429029 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with POPF (n = 45)
Number of subjects: 300
Study 27429029 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without POPF (n = 255)
Number of subjects: 300
Study 24474721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foamsclerotherapy
Number of subjects: 225
Study 23126307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 152
Study 23126307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin initiated before 16 weeks of gestation (from meta-analysis)
Number of subjects: 152
Study 23126307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 21739068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with additional support (metabolic syndrome manual book, telephone counseling, nutrition education leaflets)
Number of subjects: 0
Study 21739068 — intervention group
Group type: COMPARATOR
Intervention: Control group following the same diet without additional support
Number of subjects: 0
Study 19427269 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ascorbic acid (about 30 mg/kg/day)
Number of subjects: 81
Study 19427269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 16771779 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast + Loratadine
Number of subjects: 50
Study 16771779 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 50
Study 16771779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15541413 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of Gynol II gel
Number of subjects: 10
Study 15541413 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of Gynol II gel
Number of subjects: 10
Study 15541413 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated intercourse
Number of subjects: 10
Study 11185653 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol withdrawal (abstinence from alcohol for 4 weeks)
Number of subjects: 236
Study 11185653 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption (mean 81.8 g/d, range 40-150 g/d)
Number of subjects: 236
Study 9293612 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (1000 mg, twice daily)
Number of subjects: 643
Study 9293612 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (200 mg, 5 times daily)
Number of subjects: 643
Study 8420348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle device
Number of subjects: 25
Study 8420348 — intervention group
Group type: COMPARATOR
Intervention: Vabra aspirator
Number of subjects: 25
Study 3523662 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 19
Study 3523662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31535829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 4744
Study 31535829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 28478107 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized endobronchial photodynamic therapy (PDT) under fluorescence control, violet light 408nm, diagnostic light.
Number of subjects: 90
Study 28478107 — intervention group
Group type: COMPARATOR
Intervention: Standard PDT procedure, 662nm, pulse‐periodic mode, therapeutic light (reference group).
Number of subjects: 90
Study 26541878 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide-simeticone caplet
Number of subjects: 415
Study 26541878 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide-simeticone chewable tablet
Number of subjects: 415
Study 26541878 — intervention group
Group type: COMPARATOR
Intervention: S. boulardii
Number of subjects: 415
Study 23107580 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative reminders by telephone or in person (Group 1)
Number of subjects: 432
Study 23107580 — intervention group
Group type: EXPERIMENTAL
Intervention: Free cataract surgery (Group 2)
Number of subjects: 432
Study 23107580 — intervention group
Group type: EXPERIMENTAL
Intervention: Free surgery and reimbursement of transportation expenses (Group 3)
Number of subjects: 432
Study 23107580 — intervention group
Group type: EXPERIMENTAL
Intervention: Free rides from home to hospital in addition to the reminder and free surgery (Group 4)
Number of subjects: 432
Study 23107580 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group 2 and Group 3
Number of subjects: 432
Study 23107580 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group 2 and Group 4
Number of subjects: 432
Study 20928835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc gluconate plus corticosteroid treatment
Number of subjects: 66
Study 20928835 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 66
Study 18602474 — intervention group
Group type: EXPERIMENTAL
Intervention: MK (1.0 mg morphine + 5 mg ketamine/bolus)
Number of subjects: 58
Study 18602474 — intervention group
Group type: COMPARATOR
Intervention: MO (1.5 mg morphine/bolus)
Number of subjects: 58
Study 17140533 — intervention group
Group type: EXPERIMENTAL
Intervention: ART group (excavated with hand instruments)
Number of subjects: 217
Study 17140533 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional group (excavated with burs)
Number of subjects: 217
Study 17140533 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv group (excavation with a chemical solution and special blunt hand instruments)
Number of subjects: 217
Study 17140533 — intervention group
Group type: COMPARATOR
Intervention: Residual caries
Number of subjects: 217
Study 17140533 — intervention group
Group type: COMPARATOR
Intervention: Cervical gaps
Number of subjects: 217
Study 17140533 — intervention group
Group type: COMPARATOR
Intervention: Combination of residual caries and cervical gaps
Number of subjects: 217
Study 14523778 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir-based therapy (with or without other antiretroviral drugs)
Number of subjects: 371
Study 10921143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong Luo Kai Bi Tablets
Number of subjects: 120
Study 10921143 — intervention group
Group type: COMPARATOR
Intervention: Rheumatic Semen Strychni Tablets
Number of subjects: 120
Study 7536475 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN-alpha 2b, including nine patients with additional IFN gamma)
Number of subjects: 49
Study 7536475 — intervention group
Group type: COMPARATOR
Intervention: Busulfan (BU)
Number of subjects: 49
Study 1665177 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril-hydrochlorothiazide 20 mg and 12.5 mg (L/HCTZ)
Number of subjects: 0
Study 1665177 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 40 mg once daily (L40)
Number of subjects: 0
Study 6821404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 10% i.v.
Number of subjects: 20
Study 6821404 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 20
Study 30030330 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 144
Study 30030330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 26682721 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 8 mg
Number of subjects: 90
Study 26682721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg
Number of subjects: 90
Study 26682721 — intervention group
Group type: COMPARATOR
Intervention: Perineural saline 0.9%
Number of subjects: 90
Study 26682721 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline 0.9%
Number of subjects: 90
Study 24342681 — intervention group
Group type: EXPERIMENTAL
Intervention: MR(+)
Number of subjects: 28
Study 24342681 — intervention group
Group type: EXPERIMENTAL
Intervention: SM(+)
Number of subjects: 28
Study 24342681 — intervention group
Group type: COMPARATOR
Intervention: MR(‐)/SM(+)
Number of subjects: 28
Study 22389919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 200 mg
Number of subjects: 840
Study 22389919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 500 mg
Number of subjects: 840
Study 22389919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study 20390409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clodronate at a dose of 100 mg weekly for 12 months
Number of subjects: 91
Study 20390409 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 91
Study 18709953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran (Group A)
Number of subjects: 68
Study 18709953 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat (Group B)
Number of subjects: 68
Study 18709953 — intervention group
Group type: COMPARATOR
Intervention: Control eyes of Group A
Number of subjects: 68
Study 18709953 — intervention group
Group type: COMPARATOR
Intervention: Control eyes of Group B
Number of subjects: 68
Study 16108943 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin levels at 3 months post-discharge
Number of subjects: 282
Study 16108943 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month post-discharge albumin levels
Number of subjects: 282
Study 12418424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates administered orally and/or transdermally
Number of subjects: 0
Study 12418424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9659191 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha tocopherol (vitamin E) 50 mg/day
Number of subjects: 1795
Study 9659191 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha tocopherol (vitamin E) 50 mg/day and beta carotene 20 mg/day
Number of subjects: 1795
Study 9659191 — intervention group
Group type: EXPERIMENTAL
Intervention: beta carotene 20 mg/day
Number of subjects: 1795
Study 9659191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1795